EGFR and non-small cell lung carcinoma: In NSCLC notably, the move towards an expanded precision medicine based on individual tumor characteristics is well illustrated by the successive development of tyrosine kinase inhibitors targeting EGFR mutations, with trials comparing chemotherapy and targeted therapies systematically showing a clear superiority of targeted treatment.